1 / 43

THROMBOPHILIA

THROMBOPHILIA. Abdulkareem Almomen, MD, FRCPC KSU-MED 341 17-04- 2011 (13-05-1432). THROMBOPHILIA. Pre-Thrombotic States, Thrombogenic States, Hypercoagulable States. Hemostasis. Blood must be fluid Must coagulate (clot) at appropriate time Rapid Localized Reversible

thyra
Download Presentation

THROMBOPHILIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. THROMBOPHILIA Abdulkareem Almomen, MD, FRCPC KSU-MED 341 17-04- 2011 (13-05-1432)

  2. THROMBOPHILIA Pre-Thrombotic States, Thrombogenic States, Hypercoagulable States

  3. Hemostasis • Blood must be fluid • Must coagulate (clot) at appropriate time • Rapid • Localized • Reversible Thrombosis = inappropriate coagulation

  4. 3 Major systems involved • Vessel wall Endothelium (anti-thrombotic) • Platelets • Coagulation system coagulation factors, natural anticoagulants & fibrinolysis

  5. Vessel injury Thrombogenic Antithrombotic (Favors fluid blood) (Favorsclotting)

  6. Antithrombotic Properties of the Endothelium • Anti-platelet properties • Healthy endothelium does not bind platelets • Produce PGI-2 (prostacyclin) and NO (Nitric Oxide), which inhibit platelet binding • Produce ADP-ase which counters the platelet aggregating effects of ADP

  7. Antithrombotic Properties of the Endothelium (cont.)Anticoagulant propertiesProduce Heparin-like proteoglycans which activate anti-thrombin Produce Thrombomodulin which make a complex with thrombin (TM.T complex ) and activates protein C ,Produce tPA which activates fibrinolysis by activating plasminogen to plasmin

  8. Prothrombotic Properties of the Endothelium • Synthesis of von Willebrand factor • Release of tissue factor • Production of plasminogen activator inhibitors (PAI) • Membrane phospholipids bind and facilitate activation of clotting factors via Ca++ bridges

  9. Procoagulant Anticoagulant

  10. Procoagulant Anticoagulant

  11. Virchow’s Triad • Pathogenesis of a Thrombus Endothelial injury Abnormal blood flow Hypercoagulability • Genetic • acquired

  12. ENDOTHELIAL INJURY THROMBOSIS ABNORMAL BLOOD FLOW HYPERCOAGULABILITY

  13. Signs & Symptoms • DVT: • 50% with no clinical signs • ?Edematous extremity • Plethoric,Warm,Painful extremity • PE: • Cough, SOB, Hemoptysis • Tachycardia

  14. Intrinsic pathway XIIa Extrinsic Pathway XIa TF Prothrombin IXa VIIa VIII VIIIa Xa V Va Soft clot Thrombin Fibrinogen Fibrin XIIIa Hard clot Fibrin

  15. Physiologic Inhibitors of coagulation • Antithrombin • Activated Protein C + protein S • Inactivates Va and VIIIa (via proteolysis) • Thrombomodulin • Binds to thrombin • activate Protein C

  16. Non-physiologic inhibitors of coagulation • Vitamin K antagonists (in vivo only) • Ca chelators (in vitro only) • EDTA • Citrate • Oxalate * Heparin (in vivo and in vitro)

  17. Clot removal

  18. Fibrinolysis Plasminogen tPA Plasmin Fibrin Fibrin Split Products (FSP)

  19. Inhibitors of fibrinolysis • Plasminogen activator inhibitors (PAIs) • a2-antiplasmin (serpin)

  20. Fate of a Thrombus Diagram from Robbins Pathologic Basis of Diseases

  21. Hereditary Thrombophilias • Protein C pathway • Factor V Leiden • Protein C deficiency • Protein S deficiency • Prothrombin G20210A mutation • Antithrombin deficiency • Hyperhomocystinemia • C677T MTHFR mutation

  22. Factor V Leiden Mutation • Mutation in Factor V • Protein C/S complex • Impaired anticoagulation • 5-11% of white Europeans • Heterozygous • Autosomal dominant • Homozygous rare

  23. PAIi PAIa Platelet surface APC VIIIi VIIIa S active C4BP S inactive PC Thrombin Vi Va Thrombomodulin Endothelial surface Protein C Pathway

  24. Prothrombin G20210A mutation • Mutation in promotor • 150-200%  in prothrombin levels • 2-3% of Europeans • Heterozygous • autosomal dominant • Homozygous similar to Factor V

  25. MTHFR and Thrombosis • Hyperhomocysteinemia implicated in both arterial and venous thrombosis • Why is homocysteine thrombogenic? Theories: • Direct toxicity to endothelial cells • Inhibits Protein C activation • Promotes endothelial tissue factor expression • Surpresses endothelial cell surface heparin sulfate

  26. Hyperhomocysteinemia • Atherosclerosis, NTD, thromboembolism • Severe – homozygous • 1 in 200,000-355,000 • Cystathionine -synthase • Mild to moderate – • Heterozygotes for CS mutation • Homozygous for 667C-T MTHFR (11%)

  27. Folate and Homocysteine Metabolic Pathways

  28. Possible mechanism for role in atherogenesis, thrombogenesisLancet Vol 354, 1999

  29. AT Deficiency • Multiple mutations • Most thrombogenic disorder • Type I • Levels and activity • Type II • Activity

  30. Protein C / Protein S Deficiencies • Protein C deficiency • Type I –  number and activity • Type II –  activity • Protein S deficiency • Type I –  total and free forms • Type II –  cofactor activity • Type III -  free only • Autosomal dominant • 0.2-0.5, 0.8 prevalence

  31. PAIi PAIa Platelet surface APC VIIIi VIIIa S active C4BP S inactive PC Thrombin Vi Va Thrombomodulin Endothelial surface Protein C Pathway

  32. Antiphospholipid Antibody Syndrome • Autoimmune Acquired Prothrombotic Disorder • Very High Risk for recurrent thromboembolic disease • both venous and arterial • Indefinite duration anticoagulation recommended +/- immunosuppression • Strict Diagnostic Criteria

  33. Antiphospholipid Syndrome • Clinical criteria (≥1 must be present): 1. Vascular thrombosis: - ≥ 1clinical episode of, objectively confirmed, arterial, venous, or small vessel thrombosis 2. Pregnancy morbidity: - ≥ 1 unexplained fetal death @ ≥ 10 weeks EGA - ≥ 1 premature birth (≤ 34th week of gestation) due to eclampsia, severe pre-eclampsia, or placental insufficiency - ≥ 3 unexplained consecutive spontaneous abortions @ <10 weeks EGA Revised Sapporo/Sydney Criteria. JTH 2006;4:295-306

  34. Antiphospholipid Syndrome • Laboratory criteria (≥1 must be present): • LA (+) ≥ 2 occasions, at least 12 weeks apart, according to ISTH guidelines: • prolonged PL-based clotting assay, lack of correction with 1:1 mix, and correction with excess PL • ACLA and/or anti-β2 glycoprotein-I antibody: • medium or high IgG and/or IgM isotype titer ≥ 2 occasions, at least 12 weeks apart • Standardized ELISA assays Revised Sapporo/Sydney Criteria. JTH 2006;4:295-306

  35. Risk Factors for Thrombosis Acquired thrombophilia Hereditary thrombophilia Atherosclerosis Thrombosis Surgery trauma Immobility Estrogens Inflammation Malignancy

  36. Therapies/Heparin • Mechanism: catalysis of AT. • Neonates have lower AT levels. • Monitoring: aPTT • Problems • aPTT levels based on adult therapeutic studies. • Even in adults, therapeutic aPTT may not suggest clinically sufficient anti-coag.

  37. Therapies/Heparin • Recommended dose 75U/kg loading. • Maintenance drip dose varies: • Infants <1yr of age 28U/kg/hr • Children > 1yr 20U/kg/hr • Side effects (besides bleeding): • Heparin induced thrombocytopenia • Osteoporosis

  38. Therapies/ LMWH • Low Molecular Weight Heparin • Less monitoring needed, more predictable blood levels, less osteoporosis. • Increase dose needed for age <2mo (0.75mg Q12). >2mo (0.5mg) • Monitor anti-factor Xa levels. • In children you need to monitor , unlike adults. • Peak is 2-6hrs after injection SQ.

  39. Antithrombin Thrombin Antithrombin Factor Xa Unfractionated Heparin LMW Heparin Pentasaccharide Pentasaccharide Low Molecular Weight Heparin

  40. Therapies/Oral-anticoagulants • Impairs function of vitamin-K dependent proteins (II, VII, IX, X) plus Proteins C & S. • Newborns have reduced levels of vitamin-K dependent proteins. (Shot at birth helps.) • Vitamin K added to formulas. • Minimal in breast milk. • New anti-coagulants: Direct anti-thrombin (Daqbigatran) Anti-Xa (Rivaroxaban)

  41. Monitoring • PTT • PT/INR • TT (thrombin time) • Heparin level • Xa activity • No monitoring

  42. Anti dotes (overdose) • Stop the anti-thrombotic/anti-coagulant agent, • Protamin sulfate (heparin) • Plasma/ vitamin K (warfarin) • Tranexamic acid (thrombolytic therapy, fibrinolysis) • DDAVP (anti-platelets) • rFVIIa ( universal anti hemorrhagic) ( dose= 4000-20000 SR )

More Related